Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
Title
Roche Strengthens ADC Portfolio with $1 Billion Partnership with Oxford BioTherapeutics for Cancer Therapeutics
Keywords
Roche, Oxford BioTherapeutics, ADC, OGAP-Verify platform, cancer treatment, oncology, immuno-oncology, partnership, antibody-drug conjugate, milestone payments, drug discovery, cancer therapeutics, biobucks, first-in-class therapies.
Key Facts
- Partnership Scope:
Roche and Oxford BioTherapeutics (OBT) have finalized a multi-year collaboration focused on the discovery and development of novel cancer antibody-based therapeutics using OBT’s OGAP-Verify platform125.
- Financial Details:
* - Upfront payment:*
$36 million to OBT from Roche157.
* - Total potential milestone payments:*
Could exceed $1 billion1712.
* - Royalties:*
OBT will receive royalties on net sales of developed products57.
- Key Platform:
OBT’s OGAP-Verify discovery platform, a proprietary database with over 7,000 membrane protein profiles, will help identify novel oncology targets with improved drug development attributes47.
- Development Strategy:
- OBT will identify and validate cancer targets using the OGAP-Verify platform.
- Roche will handle further drug development, regulatory approvals, and commercialization1510.
- Therapeutic Focus:
The collaboration aims to develop multiple first-in-class immuno-oncology therapies targeting novel tumor antigens for various cancer types57.
- Strategic Goals:
This is Roche's third ADC deal in 2025, emphasizing its commitment to expanding its ADC and antibody-based therapeutic pipeline14.
- Industry Significance:
The deal highlights the increasing focus on antibody-drug conjugates (ADCs) in oncology, which are gaining traction as transformative therapies in cancer treatment51516.
Sources:
1. https://www.fiercebiotech.com/biotech/roche-continues-adc-dealmaking-spree-1b-pact-oxford-biotherapeutics
2. https://www.thepharmaletter.com/roche-partners-with-obt-on-novel-immuno-oncology-targets
4. https://www.biospace.com/business/roche-ups-adc-bet-with-1b-in-biobucks-for-oxford-biotherapeutics
5. https://www.biospace.com/press-releases/oxford-biotherapeutics-enters-into-a-strategic-collaboration-with-roche-to-discover-novel-targets-for-antibody-based-therapeutics-for-the-treatment-of-cancer
7. https://www.globenewswire.com/news-release/2025/03/19/3045140/0/en/Oxford-BioTherapeutics-Enters-into-a-Strategic-Collaboration-with-Roche-to-Discover-Novel-Targets-for-Antibody-Based-Therapeutics-for-the-Treatment-of-Cancer.html
10. https://www.americanpharmaceuticalreview.com/1315-News/618327-Oxford-BioTherapeutics-to-Collaborate-with-Roche-on-Cancer-Treatments/
12. https://endpts.com/roche-inks-1b-biobucks-deal-with-oxford-biotherapeutics-for-new-antibody-cancer-targets/
15. https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Roche-Oxford-BioTherapeutics-Team-Up-for-Antibody-based-Cancer-Therapy-Development-49373506/